| 1.39 -0.05 (-3.47%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.76  |
1-year : | 1.99 |
| Resists | First : | 1.51 |
Second : | 1.71 |
| Pivot price | 1.38 |
|||
| Supports | First : | 1.2 | Second : | 0.99 |
| MAs | MA(5) : | 1.36  |
MA(20) : | 1.44 |
| MA(100) : | 1.76 |
MA(250) : | 1.77 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 42.6 |
D(3) : | 35.5 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 2.8 | Low : | 1.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRQR ] has closed below upper band by 49.6%. Bollinger Bands are 20.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.42 - 1.43 | 1.43 - 1.43 |
| Low: | 1.32 - 1.33 | 1.33 - 1.34 |
| Close: | 1.38 - 1.39 | 1.39 - 1.4 |
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Thu, 29 Oct 2026
ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday - MarketBeat
Wed, 28 Oct 2026
Initial AX-0811 trial data are expected in early January 2027 for ProQR (PRQR). - Stock Titan
Wed, 28 Oct 2026
ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences - GlobeNewswire
Fri, 02 Oct 2026
ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Stock Price, News, Quote & History - FinancialContent
Wed, 30 Sep 2026
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow (NASDAQ:PRQR) 2026-09-30 - Seeking Alpha
Wed, 23 Sep 2026
ProQR names AI executives as clinical data nears - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 141 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 17.1 (%) |
| Held by Institutions | 53.9 (%) |
| Shares Short | 2,870 (K) |
| Shares Short P.Month | 2,460 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | -228.2 % |
| Operating Margin | -100.8 % |
| Return on Assets (ttm) | -19.8 % |
| Return on Equity (ttm) | -57.5 % |
| Qtrly Rev. Growth | 120.4 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -3.09 |
| PEG Ratio | 0 |
| Price to Book value | 2.2 |
| Price to Sales | 10.64 |
| Price to Cash Flow | -4.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|